Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 106 publications.

Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presentation to be given at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.

Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61. doi: 10.1007/s40273-023-01342-y

Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036

Earnshaw S, Brogan A, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2022 Virtual ISPOR Short Course Program; September 21, 2022. Previously presented at the 2021 Virtual ISPOR Short Course Program.

Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A. Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.

Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6

La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II - applications & design issues. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 20th Annual International Meeting.

Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2019 ISPOR 24th Annual International Meeting; May 19, 2019. New Orleans, LA. Previously presented at the ISPOR 20th Annual International Meeting.

Lucas A, Wilson M, Brogan AJ, Wasserman M, Jones D, Hilton B, Farkouh R. In small doses: missing the booster dose in a reduced pneumococcal conjugate vaccination schedule. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Earnshaw SR, Brogan AJ, Davis AE. Budget impact analysis II: applications & design issues. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 20th Annual International Meeting.

Mullins CD, Earnshaw SR, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 18th Annual European Congress.

Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X

Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293

Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.

Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II – applications and design issues. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 20, 2018. Baltimore, MD. Previously presented at the ISPOR 20th Annual International Meeting.

Wasserman M, Lucas A, Wilson M, Farkouh R, Brogan A, Hilton B, Jones D. Dynamic transmission modeling to address infant pneumococcal conjugate vaccine schedule modifications. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2017 ISPOR 20th Annual European Congress; November 5, 2017. Glasgow, Scotland. Previously presented at the ISPOR 20th Annual International Meeting.

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144

Earnshaw SR, Mullins D, Brogan A, Hogue S. Building a budget impact model: budget impact analysis training. Presented at the 2017 ISPOR Training Courses; September 2017. New Brunswick, NJ.

Brogan A, Earnshaw SR, Mauskopf J. The computing framework and calculations. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.103-28. doi: 10.1007/978-3-319-50482-7

Brogan A, Earnshaw SR, Mauskopf J. Software and computer interface. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.151-64. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Earnshaw SR, Brogan A. Creating your own budget-impact analyses today and tomorrow. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.217-24. doi: 10.1007/978-3-319-50482-7

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 20th Annual International Meeting.

Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541

Mauskopf J, Earnshaw SR, Mullins CD, Brogan A. Building a budget impact model: budget impact analysis training. Presented at the 2016 ISPOR Training Courses; November 2016. Durham, NC.

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.

Earnshaw SR, Mullins CD, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 20th Annual International Meeting.

Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 20th Annual International Meeting.

Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A214-5.

Earnshaw S, Brogan A, Wolowacz S. Budget impact analysis II: applications & design issues. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. Previously presented at the ISPOR 20th Annual International Meeting.

Talbird SE, Brogan AJ, La EH, Perard R. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in France and Spain. Poster presented at the Health Technology Assessment international; June 14, 2015. Oslo, Norway.

Earnshaw SR, Brogan AJ, Wolowacz SE. Budget impact analysis II: applications and design issues. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Earnshaw SR, Mullins CD, Brogan AJ, Wolowacz SE. Budget impact analysis: applications and design issues. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. Previously presented at the 2014 ISPOR 19th Annual International Meeting.

Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I. Cost-effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the United Kingdom. Poster presented at the 20th International AIDS Conference; July 20, 2014.

Mauskopf JA, Mullins CD, Earnshaw SR, Brogan AJ. Budget impact analysis: applications and design issues. Presented at the 2014 ISPOR 19th Annual International Meeting; June 1, 2014. Montreal, Canada.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.

Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295

Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A decision-analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the American Association for the Study of Liver Diseases; November 1, 2013.

Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Cure S. Evaluation of long-term health outcomes associated with earlier versus later initiation of treatment in previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the Annual Meeting of the American Association for the Study of Liver Diseases; November 1, 2013.